School of Biological Sciences, University of Edinburgh, King's Buildings, Mayfield Road, Edinburgh EH9 3JR, UK.
Department of Orthopaedic Surgery, University of Edinburgh, Chancellor's Building, 49 Little France, Crescent Old Dalkeith Road, Edinburgh EH16 4SB, UK.
J Med Microbiol. 2018 Jun;67(6):893-901. doi: 10.1099/jmm.0.000731. Epub 2018 Apr 19.
Despite WHO recommendations, there is currently no national screening and eradication policy for the detection of methicillin-sensitive Staphylococcus aureus (MSSA) in the UK prior to elective orthopaedic surgery. This study aimed to evaluate the effectiveness of current standard methicillin-resistant S. aureus (MRSA) eradication therapies in the context of S. aureus (both MRSA and MSSA) decolonization in an elective orthopaedic population.
A total of 100 patients awaiting joint replacement surgery who were positive for S. aureus on PCR nasal screening underwent the current standard MRSA pre-operative decolonization regimen for 5 days. Prior to commencement of the eradication therapy, swabs of the anterior nares, throat and perineum were taken for culture. Further culture swabs were taken at 48-96 h following treatment, at hospital admission for surgery and at hospital discharge. Following the completion of treatment, patients were asked to provide feedback on their experience using Likert rating scales. The primary outcome of this study was S. aureus clearance 48-96 h following eradication treatment.Results/Key Findings. Clearance of S. aureus 48-96 h following treatment was 94 % anterior nares, 66 % throat and 88 % groin. Mean completion with nasal mupirocin was 98 %. There was no statistically significant recolonization effect between the end of the eradication treatment period and the day of surgery (P>0.05) at a median time of 10 days.
Current MRSA decolonisation regimens are well tolerated and effective for MSSA decolonization for the anterior nares and groin. The decolonization effect is preserved for at least 10 days following treatment.
尽管世界卫生组织有相关建议,但目前英国在择期骨科手术前并未针对检测甲氧西林敏感金黄色葡萄球菌(MSSA)制定全国性筛查和消除政策。本研究旨在评估当前标准的耐甲氧西林金黄色葡萄球菌(MRSA)消除疗法在择期骨科人群中金黄色葡萄球菌(包括 MRSA 和 MSSA)去定植背景下的有效性。
共 100 名接受关节置换手术的患者,经 PCR 鼻拭子筛查发现金黄色葡萄球菌呈阳性,他们接受了为期 5 天的当前标准 MRSA 术前去定植方案。在开始消除治疗之前,从前鼻孔、喉咙和会阴部采集拭子进行培养。在治疗后 48-96 小时、入院进行手术时和出院时,再次采集培养拭子。治疗完成后,患者使用李克特评分量表对他们的治疗体验进行反馈。本研究的主要结局是消除治疗后 48-96 小时金黄色葡萄球菌的清除情况。
结果/主要发现:治疗后 48-96 小时,金黄色葡萄球菌在前鼻孔、喉咙和腹股沟的清除率分别为 94%、66%和 88%。鼻用莫匹罗星的平均完成率为 98%。在消除治疗期末和手术当天(中位数时间为 10 天)之间,无统计学意义的再定植效应(P>0.05)。
目前的 MRSA 去定植方案对于前鼻孔和腹股沟的 MSSA 去定植是耐受良好且有效的。治疗后至少 10 天,去定植效果得以保持。